Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

A National Bowel Cancer Screening Programme using FIT: Achievements and challenges.

O'Donoghue DP, Sheahan K, MacMathuna P, Stephens RB, Fenlon H, Morrin M, Mooney J, Fahy L, Mooney T, Smith A.

Cancer Prev Res (Phila). 2018 Dec 4. pii: canprevres.0182.2018. doi: 10.1158/1940-6207.CAPR-18-0182. [Epub ahead of print]

PMID:
30514807
2.

Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.

O'Kane GM, Ryan É, McVeigh TP, Creavin B, Hyland JM, O'Donoghue DP, Keegan D, Geraghty R, Flannery D, Nolan C, Donovan E, Mehigan BJ, McCormick P, Muldoon C, Farrell M, Shields C, Mulligan N, Kennedy MJ, Green AJ, Winter DC, MacMathuna P, Sheahan K, Gallagher DJ.

Cancer Med. 2017 Jun;6(6):1465-1472. doi: 10.1002/cam4.1025. Epub 2017 May 3.

3.

Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment.

Michielsen AJ, Noonan S, Martin P, Tosetto M, Marry J, Biniecka M, Maguire AA, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Fennelly D, Ryan EJ, O'Sullivan JN.

Mol Cancer Ther. 2012 Aug;11(8):1829-37. doi: 10.1158/1535-7163.MCT-12-0162. Epub 2012 Jun 6.

4.

Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding.

Canney AL, Kevans D, Wang LM, Hyland JM, Mulcahy HE, O'Donoghue DP, O'Sullivan J, Geraghty R, Sheahan K.

Histopathology. 2012 Sep;61(3):488-96. doi: 10.1111/j.1365-2559.2012.04250.x. Epub 2012 Mar 28.

PMID:
22463746
5.

Lipid rafts are disrupted in mildly inflamed intestinal microenvironments without overt disruption of the epithelial barrier.

Bowie RV, Donatello S, Lyes C, Owens MB, Babina IS, Hudson L, Walsh SV, O'Donoghue DP, Amu S, Barry SP, Fallon PG, Hopkins AM.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G781-93. doi: 10.1152/ajpgi.00002.2011. Epub 2012 Jan 12.

6.

Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer.

Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Ryan EJ, O'Sullivan JN.

PLoS One. 2011;6(11):e27944. doi: 10.1371/journal.pone.0027944. Epub 2011 Nov 18.

7.

A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease.

Cullen G, Keegan D, Mulcahy HE, O'Donoghue DP.

Clin Gastroenterol Hepatol. 2009 Mar;7(3):323-8; quiz 252. doi: 10.1016/j.cgh.2008.10.018. Epub 2008 Oct 30.

PMID:
19174193
8.

Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.

Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K, Leahy DT, Mulcahy HE, O'Sullivan JN.

Cancer Lett. 2009 Apr 18;276(2):228-38. doi: 10.1016/j.canlet.2008.11.018. Epub 2008 Dec 25.

PMID:
19111388
9.

Bradykinin regulates human colonic ion transport in vitro.

Baird AW, Skelly MM, O'Donoghue DP, Barrett KE, Keely SJ.

Br J Pharmacol. 2008 Oct;155(4):558-66. doi: 10.1038/bjp.2008.288. Epub 2008 Jul 7.

10.

Long-term clinical results of ileocecal resection for Crohn's disease.

Cullen G, O'toole A, Keegan D, Sheahan K, Hyland JM, O'donoghue DP.

Inflamm Bowel Dis. 2007 Nov;13(11):1369-73.

PMID:
17600379
11.

Intravenous proton pump inhibitor use in hospital practice.

Slattery E, Theyventhiran R, Cullen G, Kennedy F, Ridge C, Nolan K, Kidney R, O'Donoghue DP, Mulcahy HE.

Eur J Gastroenterol Hepatol. 2007 Jun;19(6):461-4.

PMID:
17489055
12.

Infliximab therapy in Crohn's disease: a pragmatic approach?

Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.

Aliment Pharmacol Ther. 2006 Jul 15;24(2):351-9.

13.

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di Fede G, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capellá GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, Allen-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group.

Ann Oncol. 2006 May;17(5):842-7. Epub 2006 Mar 8.

PMID:
16524972
14.

Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.

Fox EJ, Leahy DT, Geraghty R, Mulcahy HE, Fennelly D, Hyland JM, O'Donoghue DP, Sheahan K.

J Mol Diagn. 2006 Feb;8(1):68-75.

15.

Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K.

Histopathology. 2005 Aug;47(2):141-6.

PMID:
16045774
16.

CD4+CD8+ human small intestinal T cells are decreased in coeliac patients, with CD8 expression downregulated on intra-epithelial T cells in the active disease.

Carton J, Byrne B, Madrigal-Estebas L, O'Donoghue DP, O'Farrelly C.

Eur J Gastroenterol Hepatol. 2004 Oct;16(10):961-8.

PMID:
15371918
17.

Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer.

O'Keeffe J, Doherty DG, Kenna T, Sheahan K, O'Donoghue DP, Hyland JM, O'Farrelly C.

Eur J Immunol. 2004 Aug;34(8):2110-9.

18.

Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.

Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP.

Eur J Cancer. 2004 Jul;40(10):1610-6.

PMID:
15196548
19.

Percutaneous endoscopic gastrostomy: 5 years of clinical experience on 238 patients.

Sheehan JJ, Hill AD, Fanning NP, Healy C, McDermott EW, O'Donoghue DP, O'Higgins NJ.

Ir Med J. 2003 Oct;96(9):265-7.

PMID:
14753579
20.

From dinosaurs to DNA: a history of colorectal cancer.

Mulcahy HE, Hyland J, O'Donoghue DP.

Int J Colorectal Dis. 2003 May;18(3):210-5. Epub 2002 Dec 14.

PMID:
12673485
21.

Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.

Sheehan KM, O'Donovan DG, Fitzmaurice G, O'Grady A, O'Donoghue DP, Sheahan K, Byrne MF, Conroy RM, Kay EW, Murray FE.

Eur J Gastroenterol Hepatol. 2003 Apr;15(4):375-80.

PMID:
12655257
22.

Peritoneal involvement in stage II colon cancer.

Lennon AM, Mulcahy HE, Hyland JM, Lowry C, White A, Fennelly D, Murphy JJ, O'Donoghue DP, Sheahan K.

Am J Clin Pathol. 2003 Jan;119(1):108-13.

PMID:
12520705
23.

Differential expression and upregulation of interleukin-1alpha, interleukin-1beta and interleukin-6 by freshly isolated human small intestinal epithelial cells.

Madrigal-Estebas L, Doherty DG, O'Donoghue DP, Feighery C, O'Farrelly C.

Mediators Inflamm. 2002 Oct;11(5):313-9.

24.

Human duodenal epithelial cells constitutively express molecular components of antigen presentation but not costimulatory molecules.

Byrne B, Madrigal-Estebas L, McEvoy A, Carton J, Doherty DG, Whelan A, Feighery C, O'Donoghue DP, O'Farrelly C.

Hum Immunol. 2002 Nov;63(11):977-86.

PMID:
12392850
25.

Cyclosporin therapy in severe ulcerative colitis: is it worth the effort?

McCormack G, McCormick PA, Hyland JM, O'Donoghue DP.

Dis Colon Rectum. 2002 Sep;45(9):1200-5.

PMID:
12352237
26.

Sources of calcium in neurokinin A-induced contractions of human colonic smooth muscle in vitro.

O'Riordan AM, Quinn T, Hyland JM, O'Donoghue DP, Baird AW.

Am J Gastroenterol. 2001 Nov;96(11):3117-21.

PMID:
11721758
27.

Tissue cytokine and chemokine expression in inflammatory bowel disease.

McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW.

Inflamm Res. 2001 Oct;50(10):491-5.

PMID:
11713901
28.

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N.

Br J Cancer. 2001 Sep 1;85(5):692-6.

30.

Flow cytometric analysis of Clostridium difficile adherence to human intestinal epithelial cells.

Drudy D, O'Donoghue DP, Baird A, Fenelon L, O'Farrelly C.

J Med Microbiol. 2001 Jun;50(6):526-34.

PMID:
11393290
31.

Oxygen metabolites in immune- stimulated ion transport in rat colon: modulation by taurine.

Skelly MM, O'Donoghue DP, Baird AW.

Digestion. 2001;63(2):124-9.

PMID:
11244251
32.

Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer.

Curran B, Lenehan K, Mulcahy H, Tighe O, Bennett MA, Kay EW, O'Donoghue DP, Leader M, Croke DT.

Gut. 2000 Feb;46(2):200-4.

33.

Sacral dysgenesis associated with terminal deletion of chromosome 7q: a report of two families.

Wang J, Spitz L, Hayward R, Kiely E, Hall CM, O'Donoghue DP, Palmer R, Goodman FR, Scambler PJ, Winter RM, Reardon W.

Eur J Pediatr. 1999 Nov;158(11):902-5.

PMID:
10541945
34.

bcl-2 protein expression is associated with better prognosis in colorectal cancer.

Leahy DT, Mulcahy HE, O'Donoghue DP, Parfrey NA.

Histopathology. 1999 Oct;35(4):360-7.

PMID:
10564391
35.

The relationship between cyclooxygenase-2 expression and colorectal cancer.

Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE.

JAMA. 1999 Oct 6;282(13):1254-7. Erratum in: JAMA 2000 Mar 15;283(11):1427.

PMID:
10517428
36.

Berberine inhibits ion transport in human colonic epithelia.

Taylor CT, Winter DC, Skelly MM, O'Donoghue DP, O'Sullivan GC, Harvey BJ, Baird AW.

Eur J Pharmacol. 1999 Feb 26;368(1):111-8.

PMID:
10096776
37.

Crohn's colitis: the fate of the rectum.

Geoghegan JG, Carton E, O'Shea AM, Astbury K, Sheahan K, O'Donoghue DP, Hyland JM.

Int J Colorectal Dis. 1998;13(5-6):256-9.

PMID:
9870172
38.

Fulminant colitis in inflammatory bowel disease: detailed pathologic and clinical analysis.

Swan NC, Geoghegan JG, O'Donoghue DP, Hyland JM, Sheahan K.

Dis Colon Rectum. 1998 Dec;41(12):1511-5.

PMID:
9860331
39.

CD4+ CD8+ and CD8alpha+ beta- T lymphocytes in human small intestinal lamina propria.

Abuzakouk M, Carton J, Feighery C, O'Donoghue DP, Weir DG, O'Farrelly C.

Eur J Gastroenterol Hepatol. 1998 Apr;10(4):325-9.

PMID:
9855049
40.

Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K.

Clin Cancer Res. 1997 Oct;3(10):1837-40.

41.

Human small intestinal epithelial cells secrete interleukin-7 and differentially express two different interleukin-7 mRNA Transcripts: implications for extrathymic T-cell differentiation.

Madrigal-Estebas L, McManus R, Byrne B, Lynch S, Doherty DG, Kelleher D, O'Donoghue DP, Feighery C, O'Farrelly C.

Hum Immunol. 1997 Dec;58(2):83-90. Erratum in: Hum Immunol 2000 Jul;61(7):719.

PMID:
9475337
42.
43.

Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death.

Mulcahy HE, Toner M, Patchett SE, Daly L, O'Donoghue DP.

Dis Colon Rectum. 1997 Mar;40(3):326-31.

PMID:
9118749
44.

Perianal Crohn's disease.

O'Donoghue DP, Hyland JM.

Eur J Gastroenterol Hepatol. 1997 Mar;9(3):235-6. Review.

PMID:
9096421
45.

Loss of heterozygosity and microsatellite instability at the DCC and nm23 loci in Duke's B colorectal carcinoma.

Lenehan K, Mulcahy H, Curran B, Bennett MA, Kay E, O'Donoghue DP, Leader M, Croke DT.

Biochem Soc Trans. 1997 Feb;25(1):140S. No abstract available.

PMID:
9057038
46.

Screening for asymptomatic colorectal cancer.

Mulcahy HE, Farthing MJ, O'Donoghue DP.

BMJ. 1997 Jan 25;314(7076):285-91. Review. No abstract available. Erratum in: BMJ 1997 Feb 15;314(7079):497.

47.

Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis.

Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA.

J Pathol. 1996 Dec;180(4):364-70.

PMID:
9014855
48.

Bone remodeling indices and secondary hyperparathyroidism in celiac disease.

Keaveny AP, Freaney R, McKenna MJ, Masterson J, O'Donoghue DP.

Am J Gastroenterol. 1996 Jun;91(6):1226-31.

PMID:
8651176
49.

An image analysis study of DNA content in early colorectal cancer.

Kay EW, Mulcahy HE, Curran B, O'Donoghue DP, Leader M.

Eur J Cancer. 1996 Apr;32A(4):612-6.

PMID:
8695262
50.

Long-term outcome following curative surgery for malignant large bowel obstruction.

Mulcahy HE, Skelly MM, Husain A, O'Donoghue DP.

Br J Surg. 1996 Jan;83(1):46-50.

PMID:
8653361

Supplemental Content

Loading ...
Support Center